Academic Degrees

PhD in Pharmacology, 2010, HuazhongUniversity of Science and Technology, Wuhan

MS in Pharmacology, 2006, HuazhongUniversity of Science and Technology, Wuhan

MD in Clinical Medicine, 1999, Tongji Medical University, Wuhan

Professional Experience

Associate Professor (2014-present), Huazhong University of Science and Technology, Department of Pharmacology;

Lecturer (2004-2014), Huazhong University of Science and Technology, Department of Pharmacology;

Postdoctal Fellow (2011-2014), Houston Methodist Research Institute, Department of Nanomedicine;

Research Assistant (1999-2004), Huazhong University of Science and Technology, Department of Pharmacology;

Selected Publications

1.     Wang Z, Kerketta R, Chuang YL, Dogra P, Butner JD, Brocato TA, Day A, Xu R, Shen H, Simbawa E, Al-Fhaid AS, Mahmoud SR, Curley SA, Ferrari M, Koay EJ, Cristini V. Theory and experimental validation of a spatio-temporal model of chemotherapy transport to enhance tumor cell kill. PLoSComput Biol. 2016 Jun 10;12(6):e1004969.

2.    Xu R*, Zhang G*, Mai J*, Deng X*, Segura-Ibarra V, Wu S, Shen J, Liu H, Hu Z, Chen L, Huang Y, Koay E, Huang Y, Liu J, Ensor JE, Blanco E, Liu X, Ferrari M, Shen H. An injectable nanoparticle generator enhances delivery of cancer therapeutics. Nat Biotechnol. 2016 Apr;34(4):414-8.

2.    Shen J*, Xu R*, Mai J*, Kim HC, Guo X, Qin G, Yang Y, Wolfram J, Mu C, Xia X, Gu J, Liu X, Mao ZW, Ferrari M, Shen H. High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics.ACS Nano. 2013 Nov 26;7(11):9867-80.

3.    Xu R, Huang Y, Mai J, Zhang G, Guo X, Xia X, Koay EJ, Qin G, Erm DR, Li Q, Liu X, Ferrari M, Shen H. Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy.Small. 2013 May 27;9(9-10):1799-808.

4.    Xu R, Yang XY, Yang DF, Zou CY, Gong PL, Zeng FD. Phase I evaluation of the safety and pharmacokinetics of a single-dose intravenous injection of a murine monoclonal antibody against Hantaan virus in healthy volunteers. Antimicrob Agents Chemother. 2009 Dec;53(12):5055-9.

5.    Xia X, Mai J, Xu R, Perez JE, Guevara ML, Shen Q, Mu C, Tung HY, Corry DB, Evans SE, Liu X, Ferrari M, Zhang Z, Li XC, Wang RF, Shen H. Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response.Cell Rep. 2015 May 12;11(6):957-66.

6.    Zhu Y, He W, Gao X, Li B, Mei C, Xu R, Chen H. Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells.Sci Rep. 2015 Dec 4;5:17730.

7.    Mei C, Li B, Yin Q, Jin J, Xiong T, He W, Gao X, Xu R, Zhou P, Zheng H, Chen H. Liquid chromatography-tandem mass spectrometry for the quantification of flurbiprofen in human plasma and its application in a study of bioequivalence. J Chromatogr B AnalytTechnol Biomed Life Sci. 2015 Jul 1;993-994:69-74.

8.    Gizzatov A, Stigliano C, Ananta JS, Sethi R, Xu R, Guven A, Ramirez M, Shen H, Sood A, Ferrari M, Wilson LJ, Liu X, Decuzzi P. Geometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of cancer. Cancer Lett. 2014 Sep 28;352(1):97-101.

9.    Mai J, Huang Y, Mu C, Zhang G, Xu R, Guo X, Xia X, Volk DE, Lokesh GL, Thiviyanathan V, Gorenstein DG, Liu X, Ferrari M, Shen H. Bone marrow endothelium-targeted therapeutics for metastatic breast cancer.  J Control Release. 2014 Aug 10;187:22-9.

10.  Zhang M, Xu R, Xia X, Yang Y, Gu J, Qin G, Liu X, Ferrari M, Shen H.  Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells.Biomaterials. 2014 Jan;35(1):423-31.

11.   Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G.  Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.Clin Cancer Res. 2013 Apr 1;19(7):1806-15.

12.   Fan J, Huang Y, Finoulst I, Wu HJ, Deng Z, Xu R, Xia X, Ferrari M, Shen H, Hu Y. Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay. Cancer Lett. 2013 Jul 1;334(2):202-10.

13.   Zhao L, Yang X, Xu R, Wu J, Gu S, Zhang L, Gong P, Chen H, Zeng F. Safety, tolerability and pharmacokinetics of phenoprolamine hydrochloride floating sustained-release tablets in healthy Chinese subjects.Int J Pharm. 2009 Jul 30;377(1-2):99-104.

14.  Zhao L, Hu J, Chang Q, Ke Q, Xu R, Gu S, Chen H, Zeng F. A simple and sensitive HPLC method for quantitation of low phenoprolamine hydrochloride concentrations in human plasma and its pharmacokinetic application.Biomed Chromatogr. 2008 Mar;22(3):333-8.

Awards and Honors

1. Combine nanoparticle generator with breast cancer stem cell targeting therapy to treat late stage triple negative breast cancer,Natural Science Foundation of China, 2016-2020

2. Selective ATM gene silencing based on a novel siRNA multistage vector delivery system regulates triple-negative breast cancer (TNBC) chemotherapy resistance and tumor metastasis, Natural Science Foundation of China, 2014-2016

3. Nanoparticlesdelivering Rad51 siRNA to enhancechemosensitivityof TNBC, Hubei Province health and familyplanning scientific research project,2015-2017

4.  Establishment of new nano drug to treat breast cancer bone metastasis,the Fundamental Research Funds for the Central Universities, HUST, 2016-2018

Courses Taught

1409181 Clinical Pharmacology (undergraduate)

1412391 Rational Drug Use (undergraduate)

1411301 Adverse Drug Reaction (undergraduate)

510.524Clinical Pharmacology (graduate)